DYE ENHANCED VISUALIZATION OF CATARACT SURGERY
20220175971 · 2022-06-09
Assignee
Inventors
Cpc classification
A61F2/1662
HUMAN NECESSITIES
A61K49/006
HUMAN NECESSITIES
International classification
A61K9/00
HUMAN NECESSITIES
Abstract
The invention relates generally to the use of dyes to enhance visualization of tissues and boundaries of openings in tissues during cataract surgery.
Claims
1. An ophthalmic solution comprising an isotonic and pH neutral aqueous solution of Trypan Blue at a concentration greater than or equal to 0.3% and less than or equal to 0.45% by weight packaged in a syringe.
2. The ophthalmic solution of claim 1, comprising one or more other dyes that absorb in the red and orange region of the spectrum.
3. The ophthalmic solution of claim 2, wherein the one or more other dyes comprise Evans Blue.
4. The ophthalmic solution of claim 2, wherein the concentration by weight of Trypan Blue is equal to or about equal to the total concentration by weight of the one or more other dyes.
5. The ophthalmic solution of claim 2, wherein the total concentration by weight of Trypan Blue and the one or more other dyes is greater than 0.3% and less than or equal to 0.45% by weight.
6. The ophthalmic solution of claim 5, wherein the one or more other dyes comprise Evans Blue.
7. The ophthalmic solution of claim 6, wherein the concentrations by weight of Trypan Blue and Evans Blue are equal or about equal.
8. An ophthalmic solution comprising an isotonic and pH neutral aqueous solution of Trypan Blue at a concentration greater than or equal to 0.3% and less than or equal to 0.45% by weight packaged in a delivery device configured to introduce the ophthalmic solution into the anterior chamber of an eye and apply it to the anterior lens capsule in the eye.
9. The ophthalmic solution of claim 8, comprising one or more other dyes that absorb in the red and orange region of the spectrum.
10. The ophthalmic solution of claim 9, wherein the one or more other dyes comprise Evans Blue.
11. The ophthalmic solution of claim 9, wherein the concentration by weight of Trypan Blue is equal to or about equal to the total concentration by weight of the one or more other dyes.
12. The ophthalmic solution of claim 9, wherein the total concentration by weight of Trypan Blue and the one or more other dyes is greater than 0.3% and less than or equal to 0.45% by weight.
13. The ophthalmic solution of claim 12, wherein the one or more other dyes comprise Evans Blue.
14. The ophthalmic solution of claim 13, wherein the concentrations by weight of Trypan Blue and Evans Blue are equal or about equal.
15. An ophthalmic solution comprising an isotonic and pH neutral aqueous solution of Trypan Blue at a concentration greater than or equal to 0.3% and less than or equal to 0.45% by weight packaged in a delivery device configured to introduce the ophthalmic solution into the anterior chamber of an eye and apply it to lens tissue in the eye.
16. The ophthalmic solution of claim 15, comprising one or more other dyes that absorb in the red and orange region of the spectrum.
17. The ophthalmic solution of claim 16, wherein the one or more other dyes comprise Evans Blue.
18. The ophthalmic solution of claim 16, wherein the concentration by weight of Trypan Blue is equal to or about equal to the total concentration by weight of the one or more other dyes.
19. The ophthalmic solution of claim 16, wherein the total concentration by weight of Trypan Blue and the one or more other dyes is greater than 0.3% and less than or equal to 0.45% by weight.
20. The ophthalmic solution of claim 19, wherein the one or more other dyes comprise Evans Blue.
21. The ophthalmic solution of claim 20, wherein the concentrations by weight of Trypan Blue and Evans Blue are equal or about equal.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
DETAILED DESCRIPTION
[0050] The following detailed description should be read with reference to the drawings, in which identical reference numbers refer to like elements throughout the different figures. The drawings, which are not necessarily to scale, depict selective embodiments and are not intended to limit the scope of the invention. The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. This description will clearly enable one skilled in the art to make and use the invention, and describes several embodiments, adaptations, variations, alternatives, and uses of the invention, including what is presently believed to be the best mode of carrying out the invention.
[0051] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise.
[0052]
[0053]
[0054]
[0055] Referring again to
[0056] The concentration of dye in the acellular lens capsule would typically be toxic to cells in its proximity. However, the lens capsule consists of type IV collagen, not living cells. Thus, a locally high concentration for times in excess of 30 minutes in the collagen IV matrix of the lens capsule does not harm the lens capsule.
[0057] Further, the inventor has recognized that the most sensitive cells in the eye are cells in the retina and corneal endothelial cells. These cells are all distant from the lens capsule. For example, the corneal epithelium is nominally at least 2 mm away from the anterior capsulotomy. As dye molecules slowly wash out of the lens capsule at low concentration, they are further diluted as the flow enters the anterior chamber via the pupil. As a result, corneal endothelial cells may be exposed to Trypan Blue at less than 1% of the original solution concentration, for example. The sensitive retina cells are even more distant and are not directly involved in the outflow of the aqueous humor, thus will have even less exposure than 0.1% of the original solution concentration. Consequently, even though the lens capsule comprises dye at locally high concentrations, the most sensitive cells in the eye are not exposed to such high (toxic) concentrations of the dye.
[0058] The inventor has experimentally determined that the toxicity threshold is at a Trypan Blue staining solution concentration of at least 0.5%. Further, the inventor has performed preclinical and clinical testing including over 400 capsulotomies utilizing the Trypan Blue solution and staining method described above with no adverse event and no increased cell death when compared with a control group of cataract patients which received surgery with capsulotomy absent the use of Trypan Blue.
[0059] Thus, contrary to what one would expect from the toxicity concerns raised in the prior art, controlled experiments have determined that use of a Trypan Blue solution at concentrations of 0.25 to 0.45% by weight to stain the lens capsule is safe.
[0060] Referring to
[0061] The inventor has also experimentally determined that the rate at which the Trypan Blue solution stains the lens capsule increases with the concentration of Trypan Blue in the staining solution.
[0062] Thus, the inventor has determined that the use of a Trypan Blue solution at concentrations of 0.2 to 0.45% by weight to stain the lens capsule is advantageous compared to prior art preferred concentration of 0.1% (Melles, Coroneo discussed above), because it provides faster and darker staining and better visual discrimination while remaining safe to eye tissues.
[0063] The inventor has also experimentally determined with human and porcine eyes that the contrast between the stained portion of the lens capsule to unstained portions increases with the thickness of the stained region. This can be seen for example in
[0064] The inventor's experimental work implies that Trypan Blue molecules diffuse into and through the full thickness of the lens capsule. The staining rate is proportional to the concentration of Trypan Blue in the staining solution. Also, the overall dye intensity effect increases with dye concentration in the staining solution, the overall dye intensity effect increases with thickness of the stained tissue, and the Trypan Blue molecules are held in place in the collagen IV matrix of the lens capsule with temporary intermolecular bonding (likely Van der Waals bonding) allowing natural removal within a few hours.
[0065] Diffusion in to and partially through the collagen IV matrix of the lens capsule is further supported as the inventor has observed dye stained lens epithelial cell which are posterior to the anterior lens capsule utilizing Trypan Blue solutions of 0.3% or greater by weight and the staining method described above. These individual transparent cells are hard to visually identify in the absence of Trypan Blue and are responsible for some long-term complications that may occur following cataract surgery. The dye stains the living lens epithelial cells (mechanism of action is not supported in the prior art), such that as light passes through the additional stained tissue visual identified is possible due to the increased darkened appearance due to thickness of stained tissue. The surgeon would likely remove these visible stained lens epithelial cells following removal of the crystalline lens at the time of cataract surgery to reduce the probability of post-operatively complications.
[0066] Four example cases are described in greater detail below with respect to
[0067] Referring again to
[0068] Still referring to
[0069]
[0070] In this example a color shift is observed between regions dyed with Trypan Blue and undyed regions. The color shift occurs because the advanced cataract back-scatters white light, and the Trypan Blue absorbs in the green, orange and red and not strongly in the blue. The result is a blue appearance and less intensity in the stained region. This is apparent in the color image of
[0071] Such a color shift is less apparent, or not observable, with the more general case of translucent cataracts discussed below, in which visualization is based on light reflected from the retina. As further discussed below, light reflected from the retina has a low intensity of blue light, so the effect of the Trypan Blue is to absorb and reduce the intensity of the light without significantly changing its color.
[0072] In the general case, the observed light from the stained regions of the capsule is darker with less intensity because of Trypan Blue absorption, and the view appears brighter in intensity in unstained regions of the capsule. This is apparent in
[0073] Examples 2-4 discussed below all involve the white illumination light being reflected by the retina, which changes the wavelength distribution and thus the observation characteristics. These changes to the reflected spectrum are illustrated in
[0074] Retina reflectance spectrum 2300 was obtained from F. C. Delori and K. P. Pflibsen “Spectral reflectance of the human ocular fundus”, APPLIED OPTICS, 28 (6) 1989. Their data was confirmed with the inventor's experimental data.
[0075] Referring again to
[0076] In this example, white light illumination passing through the center of the capsulotomy region 12 and the crystalline lens is incident on and diffusely reflected from the retina, and the reflected light emerges from the eye along light ray 222 without passing through the capsule and thus is not modified by Trypan Blue. If the illuminating light is from a Xenon lamp, light emerging along ray 222 has the spectrum 2400 shown in
[0077] White light illumination incident on Trypan Blue stained anterior capsule portion 11 enters the eye through the stained capsule, which absorbs red and orange light. The light is then incident on and diffusely reflected by the retina, which strongly absorbs blue and green light. The light reflected by the retina then passes again through the stained anterior capsule, which again absorbs red and orange light, and exits the eye along light ray 222.
[0078]
[0079] It should be noted that the natural crystalline lens does not have a strong absorption but in mature patients has a tendency to absorb violet and blue light. This further reduces the amount of blue light being observed.
[0080] Referring again to
[0081] In this example, white light illumination passing through the center of the capsulotomy region 12 is incident on and diffusely reflected from the retina, and the reflected light emerges from the eye along light ray 232 without passing through the capsule and thus is not modified by Trypan Blue. If the illuminating light is from a Xenon lamp, light emerging along ray 232 has the spectrum 2400 shown in
[0082] White light illumination incident on Trypan Blue stained anterior capsule portion 11 enters the eye through the stained capsule, which absorbs red and orange light. The light is then incident on and diffusely reflected by the retina, which strongly absorbs blue and green light. The light reflected by the retina then passes again through the stained anterior capsule, which again absorbs red and orange light, and exits the eye along light ray 131. Light exiting along ray 131 has spectrum 2500 shown in
[0083] Referring again to
[0084] In this example, white light illumination passing through the center of the capsulotomy region 12 is incident on and diffusely reflected from the retina, and the reflected light emerges from the eye along light ray 242 without passing through the capsule and thus is not modified by Trypan Blue. If the illuminating light is from a Xenon lamp, light emerging along ray 242 has the spectrum 2400 shown in
[0085] White light illumination incident on Trypan Blue stained posterior capsule portion 4 passes through the stained posterior capsule, which slightly absorbs red and orange light. The light is then incident on and diffusely reflected by the retina, which strongly absorbs blue and green light. The light reflected by the retina then passes again through the stained posterior capsule, which again slightly absorbs red and orange light, and exits the eye along light ray 344.
[0086] White light illumination incident on Trypan Blue stained anterior capsule portion 11 enters the eye through the stained anterior capsule, which absorbs red and orange light. The light then passes through the stained posterior capsule, which slightly absorbs red and orange light, then is incident on and diffusely reflected by the retina, which strongly absorbs blue and green light. The light reflected by the retina again passes through the stained posterior capsule, which again slightly absorbs red and orange light, then again through the stained anterior capsule which again absorbs red and orange light, then exits the eye along ray 141.
[0087] Light emerging along rays 344 and 141 will have similar spectra (e.g., spectrum 2500). The net observable difference between light along rays 141, 344, and 242 is intensity, where light along ray 141 is darker, light along 344 has intermediate intensity, and light along 242 has maximum intensity from the retina reflection. The degree of the intensity shift depends on the concentration of the trypan blue solution and the thickness of the capsule that the light traverses. There is no obvious color shift between stained and unstained regions in this example.
[0088] The examples described above use a Trypan Blue solution of 0.2% to 0.45%. Other variations may use multiple dyes dissolved in a common solvent to create a solution with an accumulated concentration in the range of 0.2 to 0.45% to absorb in the red and orange region of the spectrum with a similar or greater magnitude to that of a 0.2% Trypan Blue solution. For example, Trypan Blue 0.15% in combination with Evans Blue 0.15%. The masses of these diazo dyes are somewhat similar in mass and light absorption to each, thus the combined concentration by weight of 0.2 to 0.45% is expected to yield similar results.
[0089] In addition to the uses described above, the Trypan Blue solutions describe herein may be used to increase visualization of corneal and limbal incisions.
[0090] The ophthalmic dye solutions of the present invention may be used to enhance identification and visualization of the lens capsule and capsulotomy boundary in cataract surgery methods employing direct observation of the lens capsule by a human observer, e.g. through a stereoscopic microscope, and/or by machine vision guided cataract surgery methods utilizing video cameras or other imaging devices and automated anatomical recognition. The intensity change between stained capsule regions and the capsulotomy region allows for the use of this invention with algorithms employing image intensity processing and anatomical recognition of the pupil-iris and/or limbus-iris boundary to allow calculation of the capsulotomy boundary location and determination of the tissue location. Such machine vision may be used in addition to or in combination with a conventional stereoscopic microscope. A robotic cataract surgical device can perform cataract surgery with information on anterior capsule location and its capsulotomy on a regular rate of, for example, at least 10 Hz to insert and perform phacoemulsification of the natural crystalline lens, cortical clean-up with irrigation and aspiration, removal of lens epithelial cells, formation of a posterior capsulotomy insertion and positioning of the IOL into the lens capsule.
[0091]
[0092] This disclosure is illustrative and not limiting. Further modifications will be apparent to one skilled in the art in light of this disclosure and are intended to fall within the scope of the appended claims.